Return to Today's science sparks archives

2017-08-01

Fig 1. Schematic representation of contacts between TopN and a segment of the 24-mer DNA duplex containing the 5′-CCCTT-3′ consensus sequence (spDNA).

Fig 1. Schematic representation of contacts between TopN and a segment of the 24-mer DNA duplex containing the 5′-CCCTT-3′ consensus sequence (spDNA).
  • Reed B, Yakovleva L, Shuman S, Ghose R

  • Biochemistry. 2017 Jul 5;56(26):3307-3317.

2017-08-02

Fig 1. Etv1CreERT2 temporally activates cre in the Etv1-expressing ICC subclasses.

Fig 1. Etv1CreERT2 temporally activates cre in the Etv1-expressing ICC subclasses.
  • Ran L, Murphy D, Sher J, Cao Z, Wang S, Walczak E, Guan Y, Xie Y, Shukla S, Zhan Y, Antonescu CR, Chen Y, Chi P

  • Cancer Res. 2017 Jul 15;77(14):3758-3765.

2017-08-03

Fig 1. The neurologic, oncologic, mechanicals stability and systemic disease framework.

Fig 1. The neurologic, oncologic, mechanicals stability and systemic disease framework.
  • Barzilai O, Laufer I, Yamada Y, Higginson DS, Schmitt AM, Lis E, Bilsky MH

  • J Clin Oncol. 2017 Jul 20;35(21):2419-2427.

2017-08-04

Fig 3. FOXA1 mutations act through E2F and increase tolerance to anti-oestrogen receptor treatment.

Fig 3. FOXA1 mutations act through E2F and increase tolerance to anti-oestrogen receptor treatment.
  • Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G.

  • Nature. 2017 Jul 6;547(7661):55-60.

2017-08-07

Fig 3. PCNSL is highly chemosensitive.

Fig 3. PCNSL is highly chemosensitive.
  • Grommes C, DeAngelis LM

  • J Clin Oncol. 2017 Jul 20;35(21):2410-2418.

2017-08-08

Fig 2. Model of multistage MDR development driven by perturbations in sphingomyelin, glucosylceramide and ABCB1.

Fig 2. Model of multistage MDR development driven by perturbations in sphingomyelin, glucosylceramide and ABCB1.
  • Lee WK, Kolesnick RN

  • Cell Signal. 2017 Jul 4;38:134-145.

2017-08-09

Fig 1. Chelator-free radiolabeling of SERRS nanoparticles.

Fig 1. Chelator-free radiolabeling of SERRS nanoparticles.
  • Wall MA, Shaffer TM, Harmsen S, Tschaharganeh DF, Huang CH, Lowe SW, Drain CM, Kircher MF

  • Theranostics 2017; 7(12):3068-3077.
Open Access button

2017-08-10

Fig 4. Visual monitoring of SERRS nanoparticle synthesis.

Fig 4. Visual monitoring of SERRS nanoparticle synthesis.
  • Harmsen S, Wall MA, Huang R, Kircher MF

  • Nat Protoc. 2017 Jul;12(7):1400-1414.

2017-08-11

Fig 1. Treatment response in the 16 pembrolizumab-treated patients with rrPMBCL who were evaluable (by imaging) for efficacy at the time of data cutoff.

Fig 1. Treatment response in the 16 pembrolizumab-treated patients with rrPMBCL who were evaluable (by imaging) for efficacy at the time of data cutoff.
  • Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P

  • Blood. 2017 Jul 20;130(3):267-270.

2017-08-14

Fig 1. Glucose Starvation Induces Entosis in Breast Cancer Cell Lines

Fig 1. Glucose Starvation Induces Entosis in Breast Cancer Cell Lines
  • Hamann JC, Surcel A, Chen R, Teragawa C, Albeck JG, Robinson DN, Overholtzer M

  • Cell Rep. 2017 Jul 5;20(1):201-210.
Open Access button

2017-08-15

Fig 4. Long-term rapamycin treatment slows down tumor growth in GIST-T1 and induces tumor arrest in JJ012 and CS1 in vivo.

Fig 4. Long-term rapamycin treatment slows down tumor growth in GIST-T1 and induces tumor arrest in JJ012 and CS1 in vivo.
  • Di Gialleonardo V, Aldeborgh HN, Miloushev V, Folkers KM, Granlund K, Tap WD, Lewis JS, Weber WA, Keshari KR

  • Cancer Res. 2017 Jun 1;77(11):3113-3120.

2017-08-16

Fig 1. Antitumor response and durability of dalantercept.

Fig 1. Antitumor response and durability of dalantercept.
  • Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB

  • Clin Cancer Res. 2017 Jul 15;23(14):3557-3565.

2017-08-17

Fig 8. Percentage of interferon-γ (IFN-γ) expressing cells among CD56bright and CD56dim natural killer cells from patients and controls, upon in vitro stimulation with IL-12 and IL-18. Bars represent mean ± SD values.

Fig 8. Percentage of interferon-γ (IFN-γ) expressing cells among CD56bright and CD56dim natural killer cells from patients and controls, upon in vitro stimulation with IL-12 and IL-18. Bars represent mean ± SD values.
  • Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J

  • Front Immunol. 2017 Jul 17;8:798.
Open Access button

2017-08-18

Fig 1. Levels of the Pc Mark H3K27me3 as a Function of Polymerase at Genes and Genome Wide.

Fig 1. Levels of the Pc Mark H3K27me3 as a Function of Polymerase at Genes and Genome Wide.
  • Berrozpe G, Bryant GO, Warpinski K, Spagna D, Narayan S, Shah S, Ptashne M

  • Cell Rep. 2017 Jul 25;20(4):785-793.
Open Access button

2017-08-21

Fig 5. Pathway analysis in uterine adenosarcomas and phyllodes tumors of the breast.

Fig 5. Pathway analysis in uterine adenosarcomas and phyllodes tumors of the breast.
  • Geyer FC, Burke KA, Piscuoglio S, Ng CK, Papanastasiou AD, Marchiò C, Selenica P, Edelweiss M, Murray MP, Brogi E, Soslow RA

  • Mol Oncol. 2017 Aug;11(8):913-926.
Open Access button

2017-08-22

Fig 1. Patient survival and clinical response to pembrolizumab across 12 different tumor types with mismatch repair deficiency.

Fig 1. Patient survival and clinical response to pembrolizumab across 12 different tumor types with mismatch repair deficiency.
  • Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F

  • Science. 2017 Jul 28;357(6349):409-413.

2017-08-24

Fig 5. P-Rspo3 tumours are molecularly distinct from Apc-mutant tumours.

Fig 5. P-Rspo3 tumours are molecularly distinct from Apc-mutant tumours.
  • Han T, Schatoff EM, Murphy C, Zafra MP, Wilkinson JE, Elemento O, Dow LE

  • Nat Commun. 2017 Jul 11;8:15945.
Open Access button

2017-08-25

Fig 1. Spatial and temporal heterogeneity in primary and metastatic lesions in treatment-naïve synchronous metastatic breast cancer.

Fig 1. Spatial and temporal heterogeneity in primary and metastatic lesions in treatment-naïve synchronous metastatic breast cancer.
  • Ng CK, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, De Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY

  • Clin Cancer Res. 2017 Aug 1;23(15):4402-4415.

2017-08-28

Fig 1. Mechanisms of action of commonly used systemic agents in treatment of renal cell carcinoma (RCC).

Fig 1. Mechanisms of action of commonly used systemic agents in treatment of renal cell carcinoma (RCC).
  • Shingarev R, Jaimes EA

  • Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F145-F154.

2017-08-29

Fig 1. The predicted binding mode of RXDX-105 with RET.

Fig 1. The predicted binding mode of RXDX-105 with RET.
  • Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J

  • Clin Cancer Res. 2017 Jun 15;23(12):2981-2990.

2017-08-30

Fig 3. A, Role of MRD in timing of HDT therapy in multiple myeloma schema 1. B, Role of MRD in post-HDT consolidation schema 2. C, Role of MRD in maintenance therapy in multiple myeloma schema 3. D, Role of MRD in duration of therapy in non-transplant setting schema 4.

Fig 3. A, Role of MRD in timing of HDT therapy in multiple myeloma schema 1. B, Role of MRD in post-HDT consolidation schema 2. C, Role of MRD in maintenance therapy in multiple myeloma schema 3. D, Role of MRD in duration of therapy in non-transplant setting schema 4.
  • Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M

  • Clin Cancer Res. 2017 Aug 1;23(15):3980-3993.

2017-08-31

Fig 1. Representative dose distributions of PRT versus Intensity Modulated Radiation Therapy (XRT).

Fig 1. Representative dose distributions of PRT versus Intensity Modulated Radiation Therapy (XRT).
  • Boimel PJ, Berman AT, Li J, Apisarnthanarax S, Both S, Lelionis K, Larson GL, Teitelbaum U, Lukens JN, Ben-Josef E, Metz JM

  • Journal of Gastrointestinal Oncology. 2017 Mar 22. 8(4):665-674.
Open Access button